光學臨床前影像市場規模、佔有率及成長分析（按產品、最終用途及地區）－2025 年至 2032 年產業預測

Optical Preclinical Imaging Market Size, Share, and Growth Analysis, By Product (Device, Consumables), By End Use (Pharma and Biotech Companies, Research Institutes), By Region - Industry Forecast 2025-2032

出版日期: 2025年03月20日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

光學臨床前成像市場規模預計在 2023 年達到 6.253 億美元，並從 2024 年的 6.534 億美元成長到 2032 年的 9.293 億美元，預測期內（2025-2032 年）的複合年成長率為 4.5%。

全球光學臨床前影像市場正在經歷顯著成長，活性化、對個人化醫療的日益關注以及臨床前研究中對早期發現疾病的需求。生物發光和螢光成像等介入技術可以實現生物過程的非侵入性、高解析度視覺化，提高研究人員監測疾病進展和評估治療效果的能力。儘管取得了這些進步，但該市場仍面臨著諸如成像系統高成本以及在研究中使用動物的倫理問題等挑戰。先進成像設備相關的成本可能會成為小型實驗室的障礙並限制其廣泛採用。此外，圍繞動物試驗的倫理考慮也導致了更嚴格的審查和對替代研究方法的呼籲。技術創新持續塑造市場格局。新型成像劑的開發以及人工智慧 (AI) 與成像系統的整合增強了影像分析和解釋能力，提高了臨床前研究的準確性和效率。此外，全球學術研究機構的擴張也促進了市場動態的發展。摘要：由於技術進步和研究活動的活性化，光學臨床前成像市場有望實現成長；然而，為了實現永續發展，必須解決設備成本高和道德問題等挑戰。預計持續的技術創新和研究基礎設施的擴展將在未來幾年進一步影響市場趨勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Bruker Corporation（USA）
MR Solutions（UK）
BioTek Instruments, Inc.（USA）
MILabs BV（Netherlands）
Magnetic Insight, Inc.（USA）
MBF Bioscience（USA）
FUJIFILM Corporation（Japan）
Mediso Ltd.（Hungary）
LI-COR Biosciences, Inc.（USA）
Siemens Healthineers（Germany）
General Electric（GE）Healthcare（USA）
Thorlabs, Inc.（USA）
Carl Zeiss AG（Germany）
Olympus Corporation（Japan）
Hamamatsu Photonics KK（Japan）
Berthold Technologies GmbH & Co.KG（Germany）
Endress+Hauser（Analytik Jena US LLC）（Germany/USA）
TriFoil Imaging（USA）
Vieworks Co., Ltd.（South Korea）

結論和建議

簡介目錄

Product Code: SQMIG35A2798

Optical Preclinical Imaging Market size was valued at USD 625.3 Million in 2023 and is poised to grow from USD 653.4 Million in 2024 to USD 929.3 Million by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global optical preclinical imaging market has experienced notable growth, driven by increased research and development activities in the pharmaceutical and biotechnology sectors, a heightened focus on personalized medicine, and the necessity for early disease detection in preclinical studies. Techniques such as bioluminescence and fluorescence imaging enable non-invasive, high-resolution visualization of biological processes, enhancing researchers' ability to monitor disease progression and assess treatment efficacy. Despite these advancements, the market faces challenges, including the high cost of imaging systems and ethical concerns regarding animal use in research. The expense associated with advanced imaging equipment can be a barrier for smaller research institutions, potentially limiting widespread adoption. Additionally, ethical considerations surrounding animal testing have led to increased scrutiny and calls for alternative research methods. Technological innovations continue to shape the market landscape. The development of novel imaging agents and the integration of artificial intelligence (AI) in imaging systems are enhancing image analysis and interpretation, thereby improving the accuracy and efficiency of preclinical studies. Moreover, the expansion of academic and research institutions globally contributes to the evolving dynamics of the optical preclinical imaging market. In summary, while the optical preclinical imaging market is poised for growth due to technological advancements and increased research activities, addressing challenges such as high equipment costs and ethical concerns is essential for sustainable development. Ongoing innovations and the expansion of research infrastructures are expected to further influence the market's trajectory in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Optical Preclinical Imaging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Optical Preclinical Imaging Market Segments Analysis

Global Optical Preclinical Imaging Market is segmented by Product, End Use and region. Based on Product, the market is segmented into Device, Consumables and Software. Based on End Use, the market is segmented into Pharma and Biotech Companies, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Optical Preclinical Imaging Market

The increasing demand for advanced imaging technologies in preclinical research within the pharmaceutical and biotechnology sectors has led to the adoption of optical imaging techniques, such as bioluminescence and fluorescence imaging. These methods offer non-invasive, high-resolution visualization of biological processes, providing researchers with valuable insights into disease progression and treatment efficacy. By enabling real-time monitoring of molecular and cellular activities in living organisms, optical imaging enhances the understanding of disease mechanisms and accelerates the development of targeted therapies.

Restraints in the Optical Preclinical Imaging Market

The high cost of advanced preclinical imaging systems poses a significant barrier, particularly for smaller research institutions and organizations with limited budgets. These sophisticated technologies require substantial capital investment and technical expertise, making them less accessible to entities with financial constraints. Additionally, ethical concerns regarding the use of animals in preclinical research present challenges. Researchers are increasingly encouraged to justify the necessity of animal experiments and to adhere to stringent ethical guidelines, which may involve exploring alternative methods or reducing animal usage. These factors collectively impact the adoption and implementation of advanced imaging technologies in preclinical studies.

Market Trends of the Optical Preclinical Imaging Market

The preclinical imaging field is increasingly emphasizing multimodal approaches, integrating various optical imaging techniques to obtain comprehensive and complementary data. This strategy enhances the depth and precision of studies by combining the strengths of different modalities. For instance, combining optical imaging with other modalities like MRI or PET provides both functional and anatomical information, offering a more holistic understanding of biological processes. Concurrent advancements in imaging agents, such as fluorescent probes and bioluminescent markers, have further refined visualization capabilities. Developments in fluorescence imaging probes have resulted in brighter contrast agents detectable at extremely low concentrations, enhancing sensitivity and specificity. These innovations collectively contribute to more detailed and accurate preclinical studies, facilitating a deeper understanding of disease mechanisms and the development of targeted therapies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Optical Preclinical Imaging Market Size by Product & CAGR (2025-2032)

Market Overview
Device
- Fluorescence
- Bioluminescence
Consumables
- Fluorescence
- Green Fluorescent Proteins
- Red Fluorescent Proteins
- Infrared Dyes
- Others
- Bioluminescence
- Luciferins
- Proluciferins
- Coelenterazine
- Others
Software

Global Optical Preclinical Imaging Market Size by End Use & CAGR (2025-2032)

Market Overview
Pharma and Biotech Companies
Research Institutes
Others

Global Optical Preclinical Imaging Market Size & CAGR (2025-2032)

North America (Product, End Use)
- US
- Canada
Europe (Product, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Bruker Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MR Solutions (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTek Instruments, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MILabs B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Magnetic Insight, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MBF Bioscience (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mediso Ltd. (Hungary)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LI-COR Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
General Electric (GE) Healthcare (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thorlabs, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carl Zeiss AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hamamatsu Photonics K.K. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Berthold Technologies GmbH & Co.KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endress+Hauser (Analytik Jena US LLC) (Germany/USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TriFoil Imaging (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vieworks Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments